PETALING JAYA: Hong Seng Consolidated Bhd’s subsidiary eMedAsia Sdn Bhd has entered into an exclusive partnership with CLEA Technology Sdn Bhd.
CLEA is the first company that provides CLEADOC Virtual Covid-19 professional RTK and PCR screenings (VCS) and other related services in Malaysia.
Through the partnership which involves exclusive backend system integrations, eMedAsia, a 60%-owned subsidiary under the group’s healthcare arm HS Bio Group in partnership with Koperasi Persatuan Perubatan Malaysia (KOOP MMA) which is in turn the investment arm of the Malaysia Medical Association will be able to provide CLEADOC VCS services to both the inbound and outbound travellers as preparation for the next phase of border reopening.
Hong Seng, in a statement, said CLEADOC VCS allows users to easily perform a professional pre-departure or on-arrival RTK test comfortably at anytime anywhere with results verified by medical doctors by just following the in-app steps, designed carefully by medical doctors.
It said the result generated from CLEADOC can be used as a pre-departure result requirement or Malaysia On-Arrival 24 hours requirement which are also in sync with MySejahtera status update.
KOOP MMA Chairman & eMedAsia director Dr Thirunavukarasu Rajoo said: “Malaysia is expected to welcome more than 4 million visitors while many Malaysians are expected to travel abroad following the reopening of borders. Therefore, we are ready to help our government and fellow travellers to fulfil the latest requirements to cross borders easily be it VCS, professional RTK-Ag tests in clinics or hotels, or on-site PCR screenings.”